Miura Pharmaceutical Co., Ltd. (“Miura”) today announced a cross‑domain strategy that extends from its Kampo heritage to cell‑level anti‑aging, focusing on preventive healthcare and functional nutrition. Since its founding in 2008, Miura has upheld the mission “to serve human health and keep the tree of life evergreen,” supported by a 20,000‑m² R&D campus, a team of 320 researchers, and 140+ patents. The company has built a collaboration network with 10+ research partners worldwide, including Tokyo Medical University, the California Institute of Technology, and Princeton University.
Technology & Product Innovation
Functional‑food governance system：Miura adheres to Japan’s three‑tier framework—FOSHU (Foods for Specified Health Uses), Nutrient Function Foods, and Foods with Function Claims (FFC)—and complies with MHLW GMP and third‑party testing. All products are screened for radiation and unwanted additives to promote a natural, safe, and effective approach to health.
Oral‑beauty iteration：In May 2023, Miura launched DonCoo 雪白ノ丸 (Yukishiro‑no‑Maru), applying supercritical‑fluid extraction to white tomato (rich in hydrogenated lycopenes), combined with reduced glutathione and Bifida ferment. The product reports an absorption rate of up to 94% and topped both the oral‑beauty and new‑product charts on international e‑commerce platforms in its first month.
Anti‑aging breakthrough：In 2024, Miura introduced DonCoo 还童ノ丸 (Kandō‑no‑Maru), combining catechins with French maritime pine bark extract. Its “four‑in‑one” mechanism—anti‑glycation, antioxidant action, inflammation modulation, and cellular activation—has obtained international patent protection and multi‑country quality certifications.
Global Footprint
Miura’s products reach China, Europe, the Americas, and Southeast Asia. The company advances precision medicine and health technology through collaborations with Peking University Cancer Hospital, the University of Science and Technology of China (USTC), the University of Tokyo, Stanford University, and the University of California system.
Quality & Compliance
Manufacturing conforms to PIC/S, EU, and Japan GMP standards, with third‑party verification to ensure product safety and efficacy.
Industry Impact
Market research indicates the global anti‑aging market reached US$216 billion in 2023. Miura advocates a “healthy age‑forward” paradigm—shifting the conversation from resisting aging to living well with age.
Outlook
Miura will continue to deepen R&D in cell‑level anti‑aging, precision nutrition, and smart antibody therapeutics, aiming to build a leading global health‑tech ecosystem.
About Miura Pharmaceutical
Founded in 2008 and headquartered in Tokyo, Miura innovates across cardiovascular, gastr ointestinal, oral‑beauty, and the skin microbiome fields. The company collaborates broadly with universities worldwide and holds more than 140 patents in Japan and overseas.
苏州视窗版权及免责声明：
1、凡本网来源注明“苏州视窗”的所有新闻稿件和图片作品，版权均属于苏州视窗，未经本网授权，任何单位及个人不得转载、摘编或以其它方式使用上述作品。已经本网授权使用新闻稿件和图片作品的，应在授权范围内使用，并注明“来源：苏州视窗”。违反上述声明者，本网将追究其相关法律责任。
2、凡本网注明 “来源：XXX（非苏州视窗）”的新闻稿件和图片作品，系我方转载自其它媒体，转载目的在于传递更多信息，并不代表本网赞同其观点和对其真实性负责。
3、如因新闻稿件和图片作品的内容、版权和其它问题，请及时联系本网客服：QQ64975098
我来说两句
